



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **COHN and CARSON**

Application No.: **09/658,261**

Filed: **September 8, 2000**

For: **Methods of Treating and Preventing Congestive Heart Failure With Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate**

Attorney Docket No.: **102258.288**

Assistant Commissioner of Patents
Washington, DC 20231

1614
RECEIVED
NOV 21 2001
TECH CENTER 1600/2909

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants bring to the attention of the Examiner the document listed on the attached PTO-1449 Form.


The submission of this Information Disclosure Statement does not represent that a search has been made and does not constitute an admission that the listed document is material to patentability or that the listed document is prior art.

A copy of the document listed on the attached PTO-1449 Form is submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. Accordingly, no fee is due. In the event that a fee is required, the Commissioner is authorized to charge Deposit Account No. 08-0219.

Applicants respectfully request that the Examiner initial and return a copy of the enclosed PTO-1449 form with the next communication from the Patent Office.

Respectfully submitted,



Edward D. Grieff
Registration No. 38,898

Date: November 15, 2001
HALE and DORR LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: (202) 942-8400